Analyst Price Target is $10.88
▲ +245.24% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $10.88, with a high forecast of $21.00 and a low forecast of $6.00. The average price target represents a 245.24% upside from the last price of $3.15.
Current Consensus is
The current consensus among 8 polled investment analysts is to hold stock in Fulcrum Therapeutics. This Hold consensus rating has held steady for over two years.
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.